Search This Blog

Tuesday, March 3, 2026

Teva, Blackstone Life Sciences sign $400M funding deal for phase 3 IBD drug duvakitug

 


  • Four-year strategic funding backs phase 3 development of TL1A antibody duvakitug for inflammatory bowel disease indications.
  • In return, Blackstone Life Sciences will receive future milestones and low single-digit royalties on worldwide sales.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)